Dengue fever secondary prevention: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
m (Bot: Removing from Primary care) |
||
| (7 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Dengue fever}} | {{Dengue fever}} | ||
{{CMG}} | |||
{{ | |||
==Overview== | ==Overview== | ||
Although there is no commercially available vaccine for Dengue fever, it is notable that infection with one serotype is thought to produce lifelong immunity to that type, but only short term protection against the other three. Unfortunately, the risk of severe disease from secondary infection actually increases if someone previously exposed to serotype [[DENV-1]] contracts serotype [[DENV-2]] or [[DENV-3]], or if someone previously exposed to [[DENV-3]] acquires [[DENV-2]].<ref name="pmid10460923">{{cite journal| author=Guzmán MG, Alvarez M, Rodríguez R, Rosario D, Vázquez S, Vald s L et al.| title=Fatal dengue hemorrhagic fever in Cuba, 1997. | journal=Int J Infect Dis | year= 1999 | volume= 3 | issue= 3 | pages= 130-5 | pmid=10460923 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10460923 }} </ref> | |||
Although there is no commercially available vaccine for Dengue fever, it is notable that infection with one serotype is thought to produce lifelong immunity to that type, but only short term protection against the other three. Unfortunately, the risk of severe disease from secondary infection actually increases if someone previously exposed to serotype DENV-1 contracts serotype DENV-2 or DENV-3, or if someone previously exposed to DENV-3 acquires DENV-2. | |||
==References== | ==References== | ||
| Line 13: | Line 10: | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Biological weapons]] | |||
[[Category:Flaviviruses]] | |||
[[Category:Hemorrhagic fevers]] | |||
[[Category:Insect-borne diseases]] | |||
[[Category:Neglected diseases]] | |||
[[Category:Tropical disease]] | |||
[[Category:Viral diseases]] | |||
[[Category:Emergency medicine]] | |||
[[Category:Disease]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | |||
[[Category:Hematology]] | |||
[[Category:Cardiology]] | |||
[[Category:Gastroenterology]] | |||
Latest revision as of 21:16, 29 July 2020
|
Dengue Fever Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dengue fever secondary prevention On the Web |
|
American Roentgen Ray Society Images of Dengue fever secondary prevention |
|
Risk calculators and risk factors for Dengue fever secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Although there is no commercially available vaccine for Dengue fever, it is notable that infection with one serotype is thought to produce lifelong immunity to that type, but only short term protection against the other three. Unfortunately, the risk of severe disease from secondary infection actually increases if someone previously exposed to serotype DENV-1 contracts serotype DENV-2 or DENV-3, or if someone previously exposed to DENV-3 acquires DENV-2.[1]
References
- ↑ Guzmán MG, Alvarez M, Rodríguez R, Rosario D, Vázquez S, Vald s L; et al. (1999). "Fatal dengue hemorrhagic fever in Cuba, 1997". Int J Infect Dis. 3 (3): 130–5. PMID 10460923.